Oncological outcomes of sentinel lymph node biopsy alone in patients with residual nodal disease after neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.

BACKGROUND The optimum axillary management of patients with node-positive breast cancer who have residual nodal disease (ypN+) following neoadjuvant chemotherapy (NAC) remains unclear. The aim of this systematic review was to evaluate oncological outcomes of patients with ypN + disease treated with sentinel lymph node biopsy (SLNB) only. METHODS Three major databases (PubMed, EMBASE and Scopus) were searched. The primary endpoint was 5-year overall survival. Secondary outcomes included axillary recurrence and distant recurrence rates. Only studies reporting at least one endpoint were included. Overall survival data were expressed as dichotomous variables and pooled as odds ratios using the Mantel-Haenszel method. Trial Sequential Analysis was also performed. RESULTS The final data set consisted of 9 retrospective studies, including 9889 patients. Five studies reported 5-year overall survival, 5 reported axillary recurrence rates and 4 reported rates of distant metastases. Median follow-up was 45 months (2.5-182.5). The overall weighted mean 5-year overall survival for patients undergoing SLNB alone was 85.2 % (71-93). Omission of axillary lymph node dissection (ALND) was not associated with any difference in overall survival (OR 0.90, 95 % CI 0.64-1.26, p = 0.54) or rate of axillary recurrence at 5 years (OR 1.08, 0.64-1.83, P = 0.77). CONCLUSION Omission of ALND is not associated with inferior long-term oncological outcomes in patients with a positive sentinel lymph node biopsy after NAC. Although further prospective evidence is required, it is likely that select patients with limited nodal positivity after NAC could avoid ALND and its associated morbidity.

• Publication year

  2025

• Venue

  European Journal of Surgical Oncology

• Publication date

  2025-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejso.2025.110356PMID 40811983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contemporary Axillary Surgical Management in Patients with Pathologically Node Positive Disease After Neoadjuvant Chemotherapy: A Survey of Members of the American Society of Breast Surgeons

  2024cited by this paper
• Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study

  2024cited by this paper
• Omission of Axillary Lymph Node Dissection in Patients with Residual Nodal Disease After Neoadjuvant Chemotherapy

  2024cited by this paper
• Factors Associated With Additional Axillary Disease in Patients With Positive Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Cancer

  2024cited by this paper
• Surgical Management of the Axilla in HR+/HER2– Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database

  2023cited by this paper
• Omission of Axillary Dissection in Node Positive Breast Cancer After Neoadjuvant Systemic Therapy.

  2023cited by this paper
• Changes in Surgical Management of the Axilla Over 11 Years – Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial

  2023cited by this paper
• Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial

  2022cited by this paper
• Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).

  2022cited by this paper
• Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer

  2022cited by this paper
• Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy

  2021cited by this paper
• Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

  2021cited by this paper
• Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study.

  2021cited by this paper
• Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis.

  2021cited by this paper
• Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.

  2020cited by this paper
• Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy

  2020cited by this paper
• Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer

  2020cited by this paper
• Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis

  2019cited by this paper
• Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy

  2019cited by this paper
• Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer

  2019cited by this paper
• Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

  2018cited by this paper
• Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial

  2018cited by this paper
• Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy

  2018cited by this paper
• Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer

  2018cited by this paper
• Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial

  2017cited by this paper
• Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases

  2017cited by this paper
• Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

  2015cited by this paper
• Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

  2014cited by this paper
• Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

  2013cited by this paper
• Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

  2013cited by this paper
• Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Methodological index for non‐randomized studies (MINORS): development and validation of a new instrument

  2003cited by this paper

• No citing papers are available for this paper.